<scp>JAKi</scp>: Can it be used to treat <scp>SAPHO</scp> syndrome?

Yue, Qingyun; Ma, Mingwei; Liu, Shengyan; Wu, Yuanhao; Li, Chen

doi:10.1111/1756-185x.14930

Cited by 2 publications

(1 citation statement)

References 22 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These inhibitors exhibit more significant anti-inflammatory activity compared with that of biologics that target a single cytokine. 28 Simultaneously, they contribute to regulating the expression of inflammatory factors, proving beneficial for autoimmune diseases. Additionally, baricitinib inhibits osteoclast-mediated structural damage in arthritis by blocking the receptor activator for the nuclear factor kB ligand (RANKL) pathway.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor

Yang,

Yuan,

Zhou

et al. 2024

CCID

View full text Add to dashboard Cite

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, a rare immune-mediated inflammatory disease, poses diagnostic and therapeutic challenges owing to its multi-system involvement, high heterogeneity, and lack of specific laboratory tests. Additionally, lacking evidence-based treatment recommendations, with the primary approach focusing on symptomatic relief. Herein, we report the case of a 32-year-old Chinese woman who presented with recurrent, generalized multiple osteoarticular pain lasting over one year and skin erythema pustulosis for 11 months. Traditional treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and other traditional approaches, yielded no significant effects. Despite the prior use of adalimumab and acitretin capsules, the treatment remained unsatisfying, especially regarding the skin lesions. Considering the complex pathogenesis of SAPHO syndrome, the patient was orally administered baricitinib (2 mg), a Janus kinase (JAK) inhibitor, twice daily. A notable improvement in both skin lesions and osteoarticular pain was observed within two weeks of treatment initiation. Subsequently, the dosage of baricitinib was halved and continued for an additional three months, during which regular follow-ups revealed neither disease recurrence nor adverse effects. Collectively, the successful treatment of refractory SAPHO syndrome with baricitinib presents a promising implication for addressing the therapeutic challenges of this rare autoimmune condition, offering a potential breakthrough in managing its complex manifestations.

show abstract

Section: Discussionmentioning

confidence: 99%